aluates Reports

$ 0.0

Automative

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Research Report 2025

Published Date: April 2025

Report Code: QYRE-Auto-33U13854

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Research Report 2025

Code: QYRE-Auto-33U13854

Report

April 2025

Pages:93

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Astellas Pharmaceuticals

Astrazeneca plc

Bayer

BeiGene Ltd

Bristol–Myers Squibb

Elevar Therapeutics

Eli Lilly

Incyte

MacroGenics Inc

Merck

Ono Pharmaceuticals

Roche

Daichii Sankyo

FivePrime Therapeutics

Taiho Pharmaceuticals

Zai Labs

ZymeWorks

Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size

The global market for Gastroesophageal Junction Adenocarcinoma Therapeutics was valued at US$ 7611 million in the year 2024 and is projected to reach a revised size of US$ 23880 million by 2031, growing at a CAGR of 18.0% during the forecast period.

Gastroesophageal Junction Adenocarcinoma Therapeutics Market

Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.

The gastroesophageal junction adenocarcinoma therapeutics market is driven by the increasing incidence of this aggressive cancer and the growing demand for effective treatment options. Gastroesophageal junction adenocarcinoma is a type of cancer that affects the junction between the esophagus and the stomach. The rise in risk factors, such as obesity, gastroesophageal reflux disease, and Helicobacter pylori infection, contributes to market growth. The development of targeted therapies, such as immune checkpoint inhibitors and HER2-targeted agents, has improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the late diagnosis of the disease, as it is often detected at an advanced stage, and the limited effectiveness of current treatments in advanced cases. Additionally, the high cost of specialized therapies and the need for personalized treatment approaches can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective gastroesophageal junction adenocarcinoma therapeutics.

This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Junction Adenocarcinoma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Junction Adenocarcinoma Therapeutics.

The Gastroesophageal Junction Adenocarcinoma Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastroesophageal Junction Adenocarcinoma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gastroesophageal Junction Adenocarcinoma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report

Report Metric	Details
Report Name	Gastroesophageal Junction Adenocarcinoma Therapeutics Market
Accounted market size in year	US$ 7611 million
Forecasted market size in 2031	US$ 23880 million
CAGR	18.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Drug Surgery Chemotherapy Targeted Therapy
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte, Macrogenics, Merck Co, Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroesophageal Junction Adenocarcinoma Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Gastroesophageal Junction Adenocarcinoma Therapeutics Market growing?

Ans: The Gastroesophageal Junction Adenocarcinoma Therapeutics Market witnessing a CAGR of 18.0% during the forecast period 2025-2031.

What is the Gastroesophageal Junction Adenocarcinoma Therapeutics Market size in 2031?

Ans: The Gastroesophageal Junction Adenocarcinoma Therapeutics Market size in 2031 will be US$ 23880 million.

Who are the main players in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market report?

Ans: The main players in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market are Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte, Macrogenics, Merck Co, Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks

What are the Application segmentation covered in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market report?

Ans: The Applications covered in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market report?

Ans: The Types covered in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market report are Drug, Surgery, Chemotherapy, Targeted Therapy

Recommended Reports

Gastrointestinal Cancer

Gastrointestinal Device

Gastrointestinal Therapeutics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Drug

1.2.3 Surgery

1.2.4 Chemotherapy

1.2.5 Targeted Therapy

1.3 Market by Application

1.3.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Perspective (2020-2031)

2.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Growth Trends by Region

2.2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Dynamics

2.3.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Industry Trends

2.3.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers

2.3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Challenges

2.3.4 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Revenue

3.1.1 Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue

3.4 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Concentration Ratio

3.4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in 2024

3.5 Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics Head office and Area Served

3.6 Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics, Product and Application

3.7 Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Gastroesophageal Junction Adenocarcinoma Therapeutics Breakdown Data by Type

4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Type (2026-2031)

5 Gastroesophageal Junction Adenocarcinoma Therapeutics Breakdown Data by Application

5.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2020-2031)

6.2 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025)

6.4 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2020-2031)

7.2 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025)

7.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2020-2031)

9.2 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Astellas Pharmaceuticals

11.1.1 Astellas Pharmaceuticals Company Details

11.1.2 Astellas Pharmaceuticals Business Overview

11.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.1.4 Astellas Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.1.5 Astellas Pharmaceuticals Recent Development

11.2 AstraZeneca

11.2.1 AstraZeneca Company Details

11.2.2 AstraZeneca Business Overview

11.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.2.4 AstraZeneca Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.2.5 AstraZeneca Recent Development

11.3 Bayer

11.3.1 Bayer Company Details

11.3.2 Bayer Business Overview

11.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.3.4 Bayer Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.3.5 Bayer Recent Development

11.4 Beigene

11.4.1 Beigene Company Details

11.4.2 Beigene Business Overview

11.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.4.4 Beigene Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.4.5 Beigene Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Details

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.5.4 Bristol-Myers Squibb Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 Daichii Sankyo

11.6.1 Daichii Sankyo Company Details

11.6.2 Daichii Sankyo Business Overview

11.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.6.4 Daichii Sankyo Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.6.5 Daichii Sankyo Recent Development

11.7 Elevar Therapeutics

11.7.1 Elevar Therapeutics Company Details

11.7.2 Elevar Therapeutics Business Overview

11.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.7.4 Elevar Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.7.5 Elevar Therapeutics Recent Development

11.8 Eli Lilly

11.8.1 Eli Lilly Company Details

11.8.2 Eli Lilly Business Overview

11.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.8.4 Eli Lilly Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.8.5 Eli Lilly Recent Development

11.9 FivePrime Therapeutics

11.9.1 FivePrime Therapeutics Company Details

11.9.2 FivePrime Therapeutics Business Overview

11.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.9.4 FivePrime Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.9.5 FivePrime Therapeutics Recent Development

11.10 Incyte

11.10.1 Incyte Company Details

11.10.2 Incyte Business Overview

11.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.10.4 Incyte Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.10.5 Incyte Recent Development

11.11 Macrogenics

11.11.1 Macrogenics Company Details

11.11.2 Macrogenics Business Overview

11.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.11.4 Macrogenics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.11.5 Macrogenics Recent Development

11.12 Merck Co

11.12.1 Merck Co Company Details

11.12.2 Merck Co Business Overview

11.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.12.4 Merck Co Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.12.5 Merck Co Recent Development

11.13 Ono Pharmaceuticals

11.13.1 Ono Pharmaceuticals Company Details

11.13.2 Ono Pharmaceuticals Business Overview

11.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.13.4 Ono Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.13.5 Ono Pharmaceuticals Recent Development

11.14 Roche

11.14.1 Roche Company Details

11.14.2 Roche Business Overview

11.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.14.4 Roche Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.14.5 Roche Recent Development

11.15 Taiho Pharmaceuticals

11.15.1 Taiho Pharmaceuticals Company Details

11.15.2 Taiho Pharmaceuticals Business Overview

11.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.15.4 Taiho Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.15.5 Taiho Pharmaceuticals Recent Development

11.16 Zai Labs

11.16.1 Zai Labs Company Details

11.16.2 Zai Labs Business Overview

11.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.16.4 Zai Labs Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.16.5 Zai Labs Recent Development

11.17 ZymeWorks

11.17.1 ZymeWorks Company Details

11.17.2 ZymeWorks Business Overview

11.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Introduction

11.17.4 ZymeWorks Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

11.17.5 ZymeWorks Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Astellas Pharmaceuticals

Astrazeneca plc

Bayer

BeiGene Ltd

Bristol–Myers Squibb

Elevar Therapeutics

Eli Lilly

Incyte

MacroGenics Inc

Merck

Ono Pharmaceuticals

Roche

Daichii Sankyo

FivePrime Therapeutics

Taiho Pharmaceuticals

Zai Labs

ZymeWorks

List of Tables

Table 1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Drug

Table 3. Key Players of Surgery

Table 4. Key Players of Chemotherapy

Table 5. Key Players of Targeted Therapy

Table 6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Region (2020-2025)

Table 10. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Region (2026-2031)

Table 12. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Trends

Table 13. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers

Table 14. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Challenges

Table 15. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints

Table 16. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Players (2020-2025)

Table 18. Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics as of 2024)

Table 19. Ranking of Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics, Headquarters and Area Served

Table 22. Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics, Product and Application

Table 23. Global Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Type (2020-2025)

Table 27. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Type (2026-2031)

Table 29. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Application (2020-2025)

Table 31. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Application (2026-2031)

Table 33. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 48. Astellas Pharmaceuticals Company Details

Table 49. Astellas Pharmaceuticals Business Overview

Table 50. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 51. Astellas Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 52. Astellas Pharmaceuticals Recent Development

Table 53. AstraZeneca Company Details

Table 54. AstraZeneca Business Overview

Table 55. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 56. AstraZeneca Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 57. AstraZeneca Recent Development

Table 58. Bayer Company Details

Table 59. Bayer Business Overview

Table 60. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 61. Bayer Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 62. Bayer Recent Development

Table 63. Beigene Company Details

Table 64. Beigene Business Overview

Table 65. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 66. Beigene Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 67. Beigene Recent Development

Table 68. Bristol-Myers Squibb Company Details

Table 69. Bristol-Myers Squibb Business Overview

Table 70. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 71. Bristol-Myers Squibb Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 72. Bristol-Myers Squibb Recent Development

Table 73. Daichii Sankyo Company Details

Table 74. Daichii Sankyo Business Overview

Table 75. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 76. Daichii Sankyo Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 77. Daichii Sankyo Recent Development

Table 78. Elevar Therapeutics Company Details

Table 79. Elevar Therapeutics Business Overview

Table 80. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 81. Elevar Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 82. Elevar Therapeutics Recent Development

Table 83. Eli Lilly Company Details

Table 84. Eli Lilly Business Overview

Table 85. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 86. Eli Lilly Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 87. Eli Lilly Recent Development

Table 88. FivePrime Therapeutics Company Details

Table 89. FivePrime Therapeutics Business Overview

Table 90. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 91. FivePrime Therapeutics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 92. FivePrime Therapeutics Recent Development

Table 93. Incyte Company Details

Table 94. Incyte Business Overview

Table 95. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 96. Incyte Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 97. Incyte Recent Development

Table 98. Macrogenics Company Details

Table 99. Macrogenics Business Overview

Table 100. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 101. Macrogenics Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 102. Macrogenics Recent Development

Table 103. Merck Co Company Details

Table 104. Merck Co Business Overview

Table 105. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 106. Merck Co Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 107. Merck Co Recent Development

Table 108. Ono Pharmaceuticals Company Details

Table 109. Ono Pharmaceuticals Business Overview

Table 110. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 111. Ono Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 112. Ono Pharmaceuticals Recent Development

Table 113. Roche Company Details

Table 114. Roche Business Overview

Table 115. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 116. Roche Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 117. Roche Recent Development

Table 118. Taiho Pharmaceuticals Company Details

Table 119. Taiho Pharmaceuticals Business Overview

Table 120. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 121. Taiho Pharmaceuticals Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 122. Taiho Pharmaceuticals Recent Development

Table 123. Zai Labs Company Details

Table 124. Zai Labs Business Overview

Table 125. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 126. Zai Labs Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 127. Zai Labs Recent Development

Table 128. ZymeWorks Company Details

Table 129. ZymeWorks Business Overview

Table 130. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Table 131. ZymeWorks Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025) & (US$ Million)

Table 132. ZymeWorks Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Picture

Figure 2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Drug Features

Figure 5. Surgery Features

Figure 6. Chemotherapy Features

Figure 7. Targeted Therapy Features

Figure 8. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacy Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. Online Pharmacy Case Studies

Figure 13. Gastroesophageal Junction Adenocarcinoma Therapeutics Report Years Considered

Figure 14. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Region: 2024 VS 2031

Figure 17. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Players in 2024

Figure 18. Global Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Junction Adenocarcinoma Therapeutics as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in 2024

Figure 20. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Country (2020-2031)

Figure 22. United States Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Country (2020-2031)

Figure 26. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Region (2020-2031)

Figure 34. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Country (2020-2031)

Figure 42. Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Country (2020-2031)

Figure 46. Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Astellas Pharmaceuticals Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 50. AstraZeneca Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 51. Bayer Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 52. Beigene Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 54. Daichii Sankyo Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 55. Elevar Therapeutics Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 56. Eli Lilly Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 57. FivePrime Therapeutics Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 58. Incyte Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 59. Macrogenics Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 60. Merck Co Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 61. Ono Pharmaceuticals Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 62. Roche Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 63. Taiho Pharmaceuticals Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 64. Zai Labs Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 65. ZymeWorks Revenue Growth Rate in Gastroesophageal Junction Adenocarcinoma Therapeutics Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Gastroesophageal Reflux Disease GERD Treatment Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gastrointestinal Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gastro Esophageal Reflux Disease Drug and Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Esophageal Cancer Drugs Market Insights Forecast to 2030

Global Gastrointestinal Cancer Devices Market Research Report 2024

Gastric Carcinomas Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gastrointestinal Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gastroesophageal Reflux Drugs Market

Stomach Cancer and Gastric Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Breast Adenocarcinoma Treatment Market Research Report 2024

Gastroesophageal Reflux Disease GERD Drugs and Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Stomach Cancer and Gastric Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Molecular Diagnosis in Esophageal Cancer Market Research Report 2024

Global Electronic Gastroenteritis Endoscope Market Insights Forecast to 2030

Global Stomach Cancer Drugs Market Insights Forecast to 2030

Global Gastric Electric Stimulation GES Devices Market Insights Forecast to 2030

Barrett s Esophagus Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gastric Cancer Drugs Market Research Report 2024

Global Medical Molecular Testing for Esophageal Cancer Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions